Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle

Li Zhang  
*Henry Ford Health System, lizhang3@hfhs.org*

Nadimpalli R. Varma  
*Henry Ford Health System*

Zhenggang Zhang  
*Henry Ford Health System, zzhang1@hfhs.org*

James R. Ewing  
*Henry Ford Health System, jewing1@hfhs.org*

Ali Arbab

*See next page for additional authors*

Follow this and additional works at: [https://scholarlycommons.henryford.com/neurology_articles](https://scholarlycommons.henryford.com/neurology_articles)

**Recommended Citation**

Zhang L, Varma NR, Gang ZZ, Ewing JR, Arbab AS, and Ali MM. Targeting triple negative breast cancer with a small-sized paramagnetic nanoparticle. J Nanomed Nanotechnol 2016; 7(5).

This Article is brought to you for free and open access by the Neurology at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Neurology Articles by an authorized administrator of Henry Ford Health System Scholarly Commons.
Authors
Li Zhang, Nadimpalli R. Varma, Zhenggang Zhang, James R. Ewing, Ali Arbab, and Meser M. Ali

This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/neurology_articles/314
Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle

Li Zhang¹, Nadimpalli RS Varma¹, Zhang Z. Gang¹, James R. Ewing¹, Ali S Arbab², and Meser M Ali¹,*
¹Department of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA
²Tumor Angiogenesis Laboratory, Georgia Cancer Center, Augusta University, Augusta, GA, USA

Abstract

There is no available targeted therapy or imaging agent for triple negative breast cancer (TNBC). We developed a small-sized dendrimer-based nanoparticle containing a clinical relevant MRI contrast agent, GdDOTA and a NIR fluorescent dye, DL680. Systemic delivery of dual-modal nanoparticles led to accumulation of the agents in a flank mouse model of TNBC that were detected by both optical and MR imaging. In-vivo fluorescence images, as well as ex-vivo fluorescence images of individual organs, demonstrated that nanoparticles accumulated into tumor selectively. A dual modal strategy resulted in a selective delivery of a small-sized (GdDOTA)42-G4-DL680 dendrimeric agent to TNBC tumors, avoiding other major organs.

Keywords

Triple negative breast cancer; Dual modality; MRI; Optical imaging

Introduction

Breast cancer is the second disease that kills American women than any other malignancy. Breast cancer is a wide spectrum of disease that can be categorized into different subgroups. Approximately 60-70% of breast cancers are diagnosed with the expression of estrogen receptors (ER) and/or progesterone receptors (PR). There are approximately 20-30% of breast cancers have shown the overexpressed HER2/neu receptors [1,2]. Having appropriate targets, these patients are treated with endocrine therapy or with anti-HER2 monoclonal antibody, trastuzumab [2]. There is another subtype of breast cancer that lacks appropriate targets is known as triple-negative breast cancer (TNBC) [1]. Approximately 15-20% of patients with TNBC tumors have very poor prognosis [1]. There is no available targeted therapy for these patients and they are dependent on systemic treatment options which are limited to chemotherapy [3]. Thus, there is an urgent need to develop better diagnosis and treatment option for TNBC.
The development of TNBC-targeted nanoparticles that have capability of imaging TNBC selectively holds great promise for TNBC detection and therapy. Most recent studies have found that magnetic resonance imaging (MRI) is the most sensitive test for detecting breast cancer, and is now recommended for younger women and women at high risk of the disease [4-6]. Although this sensitivity enhances the positive predictive value of MRI relative to mammography, the limited specificity of MRI for tissue type leads to unacceptable false positive results that requires subsequent evaluations [7]. Nanotechnology is a promising tool for cancer imaging and therapies. However, several important challenges have yet to be addressed before its application in cancer patients. First, it is necessary to produce nanoparticles that can selectively accumulate in the tumor environment after systemic delivery. The urgent need to develop delivery systems that target the tumor environment and inhibit tumor growth is a challenge that requires multiple functionalities. In addition, effective delivery systems should have multiple levels of selectivity, i.e. selective localization at the tumor environment and safe bio-elimination from the body without harming normal major organs.

One major advantage of nanoparticle is the effective delivery of imaging agents and cytotoxic drugs to tumor site. The leaky, irregular or defective blood vessels in tumors [8,9] allow extravasation and retention of nanoparticles. This enhanced permeation and retention (EPR) effect that has been described for nanoparticulate systems including liposomes, dendrimers, micelles and polymers [10-12]. Liposomal and protein aggregate-based delivery systems that employ EPR have been successfully introduced into the clinic as tumor targeted drug delivery systems. These include liposomal formulations of doxorubicin (Doxil/Caelyx and Myocet) and a nanoparticulate albumin-conjugated paclitaxel (Abraxane). In addition to potential improvements in tumor biodistribution, EPR also reduces the concentration of free drug (i.e. non-nanoparticle associated) in the blood, thereby limiting systemic toxicity and side effects; in practice much of the advantage of cytotoxic nanomedicines comes from their improved safety profile [13,14]. Despite the potential benefits of the currently marketed liposomal doxorubicin delivery systems, problems remain. For example, cardiotoxicity, although reduced, is still evident [15,16] and Doxil/Caelyx use is commonly associated with the development of palmar plantar erythematosis (PPE). PPE, which manifests as a painful swelling of the hands and feet is believed to reflect the gradual accumulation and nonspecific release of doxorubicin in the extremities. PPE ultimately requires a reduction in the administered dose and therefore less effective treatment [17].

The limitations of the current treatments have stimulated interest in alternate approaches to doxorubicin delivery via EPR. For example, a micellar formulation of doxorubicin (NK911) has been evaluated and shown to reduce the \textit{in vivo} incidence of toxicity, and to provide improved chemotherapeutic activity when compared to a simple solution formulation of doxorubicin [18,19]. The micellar system also demonstrated improved tumor penetration in an in vitro tumor spheroid model when compared to Doxil [12], presumably due to the small particle size of the micellar formulation (~40 nm).

Dendritic polymers, or dendrimers, provide an alternate template for the construction of nanoparticulate drug delivery systems. Dendrimers have advantages over other particles due to its smaller particle size [20] (~3-12 nm) and therefore potentially improved tumor...
penetration while still avoiding toxicity. To design and synthesize a multifunctional nanoparticle, e.g., for imaging and treatment, it is equally important that such multifunctional nanoparticles not only generate strong signals or contrast for \textit{in vivo} imaging, but also have a chemically active surface with variety of functional groups for conjugation of tumor targeting ligands and imaging agents.

Dendrimer-based PARACEST (Paramagnetic chemical exchange saturation transfer) agent containing a near infrared (NIR) dye has been developed and also detected in an experimental model of rat glioma by \textit{in vivo} CEST MRI \cite{21}. Recently, we synthesized a dendrimer-based dual modality nanoprobe and delivered across tumor blood brain barrier in rat glioma \cite{22}. Here, we report a smaller G4 dendrimer containing a clinically relevant contrast agent, Gd-DOTA, and DL680 for targeted noninvasive imaging of TNBC.

\textbf{Materials and Methods}

Animal experiments were conducted according to NIH guidelines and the experimental protocol was approved by the institutional Animals Care and User Committee (IACUC) by Henry Ford Hospital. MDA-MB-231 cells were cultured and a subcutaneous mouse model was created as described in our published methods \cite{23-25}. All reagents were purchased from commercial sources, and used as received unless otherwise stated. The ethylene core G4 PAMAM dendrimer from Dendritech Inc. (Midland, MI) was purchased as a 20% solution in methanol. The bifunctional ligand S-2-(4-Isothiocyanatobenzyl)-1, 4, 7, 10-tetraazaacyclododecane-tetraacetic acid (p-SCN-BnDOTA) was purchased from Macrocyclics, Inc. (Dallas, TX) \cite{22}. Diafiltration membranes (Amicon-Ultra MWCO 10 kDa) were obtained from Millipore (Billerica, MA) \cite{22}. Dendritic conjugates and chelates were purified by repeated diafiltration \cite{22}. Matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass spectra were acquired at Scripps Center. We measured Gd$^{3+}$ content by inductively coupled plasma-mass spectrometry (ICP-MS) at Chemical Solutions Ltd.

\textbf{MRI methods}

The $T_1$ relaxivity of (GdDOTA)$_{42}$-G4-DL680 were measured at 35°C, based on our previous reports \cite{21,26} in 7 Tesla magnet in a Varian (Santa Clara, California) 20 cm horizontal bore system with a Direct Drive spectrometer and console. Gradient maximum strengths and rise times were 250 mT/m and 120 μs. All MRI image sets were acquired with a 32 $\times$ 32 mm$^2$ FOV. The transmit coil was a Bruker-supplied volume resonator, and the receive coil was a Bruker 2 cm surface coil \cite{22}.

T1-weighted imaging used the following parameters: field of view 26 $\times$ 26 mm, 128 $\times$ 128 matrix, 27 0.4 mm slices, 0.1 mm gap, TR/TE=800/15.7 ms, NEX=4. Images were acquired before and after administration of (GdDOTA)$_{42}$-G4-DL680.

\textbf{Optical imaging}

Near-infrared (NIR) optical imaging of the mouse was conducted as described in our previous report \cite{22} by using a Kodak Carestream Multispectral Imaging System (Carestream, USA). Briefly, we acquired fluorescence images using multiple excitation...
wavelength filters ranging from 540 to 690 nm and a single emission wavelength filter of 750 nm [22]. An X-ray image was also obtained to locate the tumor as well as major organs. The Fluorescence and X-ray images were overlaid.

**Synthesis of (DOTA)$_{42}$-G4-PAMAM**

(DOTA)$_{42}$-G4-PAMAM was synthesized by following our recent published method [22], except G4-PAMAM dendrimer (0.04 g, 2.8 μmol) instead of G5 dendrimer and p-SCN-Bn-DOTA (0.125 g, 184 μmol) were used. The purification of the final conjugate was conducted by diafiltration using a Centricon C-10 membrane filter (a 10 kDa molecular weight cut-off). A colorless white solid (0.24 g) was obtained after lyophilization.

Synthesis of [Gd-(DOTA)$_{42}$]-G4-PAMAM: Complexation of Gd$^{3+}$ with (DOTA)$_{42}$-G4-PAMAM conjugate was conducted using our previously published methods [22-27]. Briefly, GdCl$_3$ (1.2 equivalent) in H$_2$O was added slowly to a stirred solution of (DOTA)$_{42}$-G4-PAMAM (0.027 g) in H$_2$O (pH 6-7) at 40 °C for 48 h. We added EDTA to remove free metal ions from the reaction mixture. The solution was filtered using Amicon Ultra 10 kDa MWCO filter. Finally, the solution was lyophilized to yield 0.018 g of white solid. MALDI-TOF mass spectrometry was used to estimate the average number of GdDOTA chelates conjugated to G4 PAMAM dendrimer (Figure S1).

Synthesis of (GdDOTA)$_{42}$-G4-DL680: The synthesis of (GdDOTA)$_{42}$-G4-DL680 (Figure 1) was conducted by following our recent report [27]. The same procedure [22,27] was used to determine the labeling degree of DL680. There are on average 1.2 molecules of DL680 are present in each dendrimer.

**Results and Discussion**

In this work, we conjugated the clinically relevant contrast agent p-SCN-Bn-GdDOTA to a G4 dendrimer and obtained (GdDOTA)$_{42}$-G4. MALDI-TOF mass spectroscopy demonstrated there to be an average of 42-GdDOTA molecules per G4 PAMAM dendrimer (Figure S1). The $r_1$ relaxivity of (GdDOTA)$_{42}$-G4-DL680 was estimated at 7T to be 5.01 mM$^{-1}$s$^{-1}$ per Gd$^{3+}$.

Both uptake in the tumor, and clearance of the compound, are critically important in the potential utility of nanoparticle therapies. In previous efforts, we conjugated p-SCN-Bn-DOTA to the amines on the surface of a generation 5 (G5) PAMAM dendrimer by using isothiocyanatobenzyl group in our recent report [22]. We also prepared TmDOTA-G4 chelate [26]. We studied the in vivo pharmacokinetics and biodistribution for these G3 and G5 dendrimer-based nanoparticles. The G3-based agent showed only rat glioma selective biodistribution, while the G5-based agent showed both glioma and liver specific biodistribution [22-30]. In these previous reports, we demonstrated that a G3-based agent is excreted through kidney [30] while the G5-based agent is excreted through liver [22]. These results are consistent with that of Kobayashi et al, in which it is reported that PAMAM dendrimer-based agents from generation G1 to G4 are excreted through kidney. Herein, we follow these previous studies, with an investigation of the pharmacokinetics and
biodistribution of a G4-based (GdDOTA)\textsubscript{42}-G4-DL680 (Figure 1) agent in a subcutaneous TNBC tumor model.

We have performed a number of dynamic contrast-enhanced (DCE) MRI studies with T1 MRI contrast agents to evaluate the efficacy of anti-angiogenic chemotherapeutics [28,29]. A solution of 0.04 mmol/kg Gd dose of (GdDOTA)\textsubscript{42}-G4-DL680 (10 mM in 100 μL PBS) was injected via the tail vein in mice bearing subcutaneous TNBC. In the 30 minutes after injection, homing of the nanoparticle was visualized in the TNBC tumor (Figure 2). In the same mouse one hour after acquisition of the MRI scan, optical imaging demonstrated that macroscopic fluorescence imaging agreed with the locus of GdDOTA-G4-DL680 identified by in the MDA-MB-231 tumor. \textit{In vivo} NIR fluorescence imaging demonstrated that the nanoparticle accumulated in the subcutaneous tumor (Figure 3A). 24 hrs after nanoparticle administration, NIR optical imaging showed that preferential accumulation of nanoparticles at the tumor site. Figure 3B and 3C demonstrate the results of post-mortem ex-vivo optical imaging in the organs and tumor of mice with TNBC tumor. Compared to organs in which it might be expected that the nanoparticle could accumulate, the tumor demonstrates a higher fluorescence signal. This excellent contrast ratio, suggests that (GdDOTA)\textsubscript{42}-G4-DL680 mostly accumulates in tumor. Then, the flank tumor was snap-frozen and sectioned into 10 to 15 μm slices for further fluorescence analysis. This \textit{ex vivo} fluorescence imaging further demonstrated the spatial specificity of the \textit{in vivo} MRI imaging, which showed the selective accumulation of the particles in the flank tumor tissue (Figure 3D). These results demonstrate that the intravenously administered small nano-sized nanoparticle (Figure 1) was able to target TNBC tumor. Therefore, TNBC tumor selective drug delivery and imaging can be accomplished by using a G4 dendrimer-based nanoparticles that possess long blood half-lives.

**Conclusion**

If a drug or imaging agent for TNBC tumors lacks targeting specificity, it can distribute to other organs and tissues, resulting in limited therapeutic effects toward the tumor and possibly severe drug-induced systemic toxic side effects. To bypass nonspecific distribution of nanoparticle, we developed a nanoparticle that used a G4 PAMAM dendrimer containing the clinically relevant MRI contrast agent, Gd-DOTA, with the addition of a fluorescent dye for further post-mortem comparisons of preferential lodgment in the tumor. Using both MRI and fluorescence imaging, we observed the successful accumulation of GdDOTA)\textsubscript{42}-G4-DL680 nanoparticle in an aggressive TNBC tumor despite its systemic delivery. We conclude that, (GdDOTA)\textsubscript{42}-G4-L680 to TNBC has the potential to use as a nanocarrier for drug delivery and imaging with minimal toxic effects on normal tissues or organs.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

The authors thank colleagues at the NMR core center, particularly Dr. Guangliang Ding for help with MRI sequences, and Dr. Robert Knight for help in setting up our experimental methods. We are grateful for the support...
of grants from the National Institutes of Health (R01 CA206190 to MMA and R01CA160216 and R01 CA172048 to ASA).

References

1. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast cancer research and treatment. 2011; 125:627–636. [PubMed: 21161370]
2. Qi Y, Fu X, Xiong Z, Zhang H, HiI SM, et al. Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PloS one. 2012; 7:e31539. [PubMed: 22348099]
3. Bayraktar S, Gluck S. Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast cancer research and treatment. 2013; 138:21–35. [PubMed: 23358903]
4. Becker C, Lacchini S, Muotri AR, da Silva GJ, Castelli JB, et al. Skeletal muscle cells expressing VEGF induce capillary formation and reduce cardiac injury in rats. International journal of cardiology. 2006; 113:348–354. [PubMed: 16675047]
5. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. The New England journal of medicine. 2004; 351:427–437. [PubMed: 15282350]
6. deCarvalho AC, Nelson K, Lemke N, Lehman NL, Arbab AS, et al. Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells. 2010; 28:181–190. [PubMed: 19937755]
7. Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005; 103:1898–1905. [PubMed: 15800894]
8. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor-tropic accumulation of proteins and the antitumor agent smancs. Cancer research. 1986; 46:6387–6392. [PubMed: 2946403]
9. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of controlled release: official journal of the Controlled Release Society. 2000; 65:271–284. [PubMed: 10699287]
10. Chang WT, Pan CY, Rajanbabu V, Cheng CW, Chen JY. Tilapia (Oreochromis mossambicus) antimicrobial peptide, hepcidin 1-5, shows antitumor activity in cancer cells. Peptides. 2011; 32:342–352. [PubMed: 21093514]
11. Borner MM. Therapeutische Umschau. Revue therapeutique. 2006; 63:243–248. [PubMed: 16689454]
12. Fujisawa H, Koide N, Kono T, Takayama K, Tsukioka K, et al. Expression of basic fibroblast growth factor and its receptor-1 in cardiac myxoma. The Journal of cardiovascular surgery. 2002; 43:589–594. [PubMed: 12386568]
13. Lammers T, Storm G, Kiessling F. Nanomedicine formulations for combination therapies. Nano reviews. 2010
14. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. British journal of cancer. 2008; 99:392–397. [PubMed: 18648371]
15. Cheng CM, Li H, Gasman S, Huang J, Schiff R, et al. Compartamentalized Ras proteins transform NIH 3T3 cells with different efficiencies. Molecular and cellular biology. 2011; 31:983–997. [PubMed: 21189290]
16. Linch M, Stavridi F, Hook J, Barbuchano Y, Gore M, et al. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecologic oncology. 2008; 109:27–32. [PubMed: 18262259]
17. Lorusso D, Di Stefano A, Carone V, Fagotti A, Piccioni S, et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome). Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2007; 18:1159–1164.
18. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. British journal of cancer. 2004; 91:1775–1781. [PubMed: 15477860]
19. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, et al. Development of the polymer micelle carrier system for doxorubicin. Journal of controlled release: official journal of the Controlled Release Society. 2001; 74:295–302. [PubMed: 11489509]

20. Sarin H. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies. Recent patents on CNS drug discovery. 2010; 5:239–252. [PubMed: 20722627]

21. Ali MM, Bhuiyan MP, Janic B, Varma NR, Mikkelsen T, et al. A nanosized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma. Nanomedicine (Lond). 2012; 7:1827–1837. [PubMed: 22891866]

22. Karki K, Ewing JR, Ali MM. Targeting Glioma with a Dual Mode Optical and Paramagnetic Nanoprobe across the Blood-brain Tumor Barrier. J Nanomed Nanotechnol. 2016

23. Ali MM, Yoo B, Pagel MD. Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. Molecular pharmaceutics. 2009; 6:1409–1416. [PubMed: 19298054]

24. Ali MM, Liu G, Shah T, Flask CA, Pagel MD. Using two chemical exchange saturation transfer magnetic resonance imaging contrast agents for molecular imaging studies. Accounts of chemical research. 2009; 42:915–924. [PubMed: 19514717]

25. Jardim-Perassi BV, Arbab AS, Ferreira LC, Borin TF, Varma NR. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PloS one. 2014; 9:e85311. [PubMed: 24416386]

26. Bhuiyan MP, Aryal MP, Janic B, Karki K, Varma NR, et al. Concentration-independent MRI of pH with a dendrimer-based pH-responsive nanoprobe. Contrast media and molecular imaging. 2015; 10:481–486. [PubMed: 26173742]

27. Huang Y, Coman D, Hyder F, Ali MM. Dendrimer-Based Responsive MRI Contrast Agents (G1-G4) for Biosensor Imaging of Redundant Deviation in Shifts (BIRDS). Bioconjugate chemistry. 2015; 26:2315–2323. [PubMed: 26497087]

28. Ali MM, Janic B, Babajani-Feremi A, Varma NR, Iskander AS, et al. Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PloS one. 2010; 5:e8727. [PubMed: 20090952]

29. Ali MM, Kumar S, Shankar A, Varma NR, Iskander AS, et al. Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. Translational oncology. 2013; 6:660–669. [PubMed: 24466368]

30. Gamage NH, Jing Li, Worsham MJ, Ali MM. Targeted Theranostic Approach for Glioma Using Dendrimer-Based Curcumin Nanoparticle. J Nanomed Nanotechnol. 2016
Figure 1.
Representation of Gd$^{3+}$ chelated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-(DOTA) in a G4 PAMAM dendrimer with DyLight (DL680).
Figure 2.
T\textsubscript{1}-weighted MR images, pre-injection (A) and post-injection (B) of GdDOTA-G4-DL680 nanoparticle in a subcutaneous flank tumor mouse model of MDA-MB-231 TNBC (dotted red circle). The agent was injected i.v. at 0.04 mmol/kg Gd dose, and detected using a T\textsubscript{1}-weighted MRI method at 7T Varian scanner. (C) Hematoxylin-eosin staining of MDA-MB-231 tumor (T).
Figure 3.
(A) The whole-body NIR fluorescence image overlaid on an x-ray image showed the presence of (GdDOTA)$_{42}$-G4-DL680 in the flank tumor of MDA-MB-231, as indicated dotted circle. (B and C) Ex-vivo light and fluorescence imaging of various organs of a mouse. Distribution of nanoparticles in organs: Light (B) and NIR (C) fluorescence images of tumor (1), kidney (2), spleen (3), liver (4), heart and lung (5) and brain (6) obtained from a mouse bearing a tumor after 24 post injection of (GdDOTA)$_{42}$-G4-DL680 agent. (D) Ex-vivo fluorescence imaging of the flank tumor section (15 micron thick frozen flank tumor tissue section) clearly showed the accumulation of (GdDOTA)$_{42}$-G4-DL680 in the tumor selectively. Non-specific accumulation of the particles was not observed.